Bruker Corporation reported full-year 2024 revenues of $3.37 billion, representing a 14% increase from fiscal year 2023. This growth included 4.0% organic growth, which was above the broader Life Science Tools & Diagnostics market.
The company's non-GAAP earnings per share (EPS) for fiscal year 2024 were $2.41, a decrease compared to $2.58 in fiscal year 2023. This decline in EPS was attributed to the initial dilution from strategic acquisitions made during the year.
Bruker's strategic acquisitions in 2024, including ELITech, Chemspeed, and NanoString, contributed 10% inorganic revenue growth. The company is actively working to integrate these businesses and put them on a path to profitability, aiming for strong growth and margin expansion in the coming years.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.